Blocking the GATA-3 pathway to inhibit the downstream release of cytokines resulted in clinical response and mucosal healing in patients with ulcerative colitis, a new study has found.
The efficacy and safety of SB012, a first-in-class compound from Sterna Biologicals, were evaluated in the randomized, double-blind SECURE trial of 20 patients with active disease—the first study to evaluate a DNAzyme in this patient population. The findings were reported at the 2018 Digestive Disease Week